1. Home
  2. ERAS vs PERI Comparison

ERAS vs PERI Comparison

Compare ERAS & PERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • PERI
  • Stock Information
  • Founded
  • ERAS 2018
  • PERI 1999
  • Country
  • ERAS United States
  • PERI Israel
  • Employees
  • ERAS N/A
  • PERI N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • PERI EDP Services
  • Sector
  • ERAS Health Care
  • PERI Technology
  • Exchange
  • ERAS Nasdaq
  • PERI Nasdaq
  • Market Cap
  • ERAS 432.6M
  • PERI 395.5M
  • IPO Year
  • ERAS 2021
  • PERI 2006
  • Fundamental
  • Price
  • ERAS $1.37
  • PERI $8.17
  • Analyst Decision
  • ERAS Strong Buy
  • PERI Hold
  • Analyst Count
  • ERAS 6
  • PERI 5
  • Target Price
  • ERAS $4.83
  • PERI $10.33
  • AVG Volume (30 Days)
  • ERAS 1.8M
  • PERI 361.7K
  • Earning Date
  • ERAS 03-20-2025
  • PERI 05-07-2025
  • Dividend Yield
  • ERAS N/A
  • PERI N/A
  • EPS Growth
  • ERAS N/A
  • PERI N/A
  • EPS
  • ERAS N/A
  • PERI 0.25
  • Revenue
  • ERAS N/A
  • PERI $498,286,000.00
  • Revenue This Year
  • ERAS N/A
  • PERI N/A
  • Revenue Next Year
  • ERAS N/A
  • PERI $5.24
  • P/E Ratio
  • ERAS N/A
  • PERI $32.64
  • Revenue Growth
  • ERAS N/A
  • PERI N/A
  • 52 Week Low
  • ERAS $1.23
  • PERI $7.47
  • 52 Week High
  • ERAS $3.45
  • PERI $22.65
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 39.36
  • PERI 43.36
  • Support Level
  • ERAS $1.40
  • PERI $7.87
  • Resistance Level
  • ERAS $1.61
  • PERI $8.21
  • Average True Range (ATR)
  • ERAS 0.11
  • PERI 0.26
  • MACD
  • ERAS 0.01
  • PERI 0.00
  • Stochastic Oscillator
  • ERAS 4.00
  • PERI 31.00

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

Share on Social Networks: